Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
Creative Medical Technology Holdings (NASDAQ: CELZ) has secured agreements for the immediate exercise of warrants, generating approximately $3.7 million in gross proceeds. The agreement involves existing warrant holders purchasing 837,104 shares at $4.42 per share, with these shares already registered under Form S-1.
In exchange for the immediate cash exercise, CELZ will issue new unregistered warrants for up to 1,674,208 shares at an exercise price of $3.75 per share, exercisable for five years following shareholder approval. The transaction, with Roth Capital Partners as financial advisor, is expected to close around March 6, 2025.
The company plans to use the net proceeds for working capital and general corporate purposes. The new warrants are offered through private placement and will require SEC registration for resale of the underlying shares.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha ottenuto accordi per l'esercizio immediato di warrant, generando circa 3,7 milioni di dollari in proventi lordi. L'accordo coinvolge i detentori di warrant esistenti che acquistano 837.104 azioni a 4,42 dollari per azione, con queste azioni già registrate sotto il modulo S-1.
In cambio dell'esercizio immediato in contante, CELZ emetterà nuovi warrant non registrati per un massimo di 1.674.208 azioni a un prezzo di esercizio di 3,75 dollari per azione, esercitabili per cinque anni dopo l'approvazione degli azionisti. La transazione, con Roth Capital Partners come consulente finanziario, dovrebbe chiudersi intorno al 6 marzo 2025.
L'azienda prevede di utilizzare i proventi netti per il capitale circolante e scopi aziendali generali. I nuovi warrant sono offerti tramite collocamento privato e richiederanno la registrazione presso la SEC per la rivendita delle azioni sottostanti.
Creative Medical Technology Holdings (NASDAQ: CELZ) ha asegurado acuerdos para el ejercicio inmediato de warrants, generando aproximadamente 3.7 millones de dólares en ingresos brutos. El acuerdo involucra a los tenedores de warrants existentes que compran 837,104 acciones a 4.42 dólares por acción, con estas acciones ya registradas bajo el formulario S-1.
A cambio del ejercicio inmediato en efectivo, CELZ emitirá nuevos warrants no registrados por hasta 1,674,208 acciones a un precio de ejercicio de 3.75 dólares por acción, ejercitables durante cinco años después de la aprobación de los accionistas. Se espera que la transacción, con Roth Capital Partners como asesor financiero, se cierre alrededor del 6 de marzo de 2025.
La empresa planea utilizar los ingresos netos para capital de trabajo y fines corporativos generales. Los nuevos warrants se ofrecen a través de colocación privada y requerirán registro ante la SEC para la reventa de las acciones subyacentes.
Creative Medical Technology Holdings (NASDAQ: CELZ)는 즉각적인 워런트 행사를 위한 계약을 체결하여 약 370만 달러의 총 수익을 창출했습니다. 이 계약은 기존 워런트 보유자가 주당 4.42달러로 837,104주를 구매하는 것을 포함하며, 이 주식은 이미 S-1 양식에 등록되어 있습니다.
즉각적인 현금 행사에 대한 대가로 CELZ는 1,674,208주에 대해 주당 3.75달러의 행사 가격으로 새로운 비등록 워런트를 발행할 예정이며, 주주 승인 후 5년 동안 행사할 수 있습니다. Roth Capital Partners가 재무 자문사로 참여하는 이번 거래는 2025년 3월 6일경에 마무리될 것으로 예상됩니다.
회사는 순수익을 운영 자본 및 일반 기업 목적에 사용할 계획입니다. 새로운 워런트는 사모 배치를 통해 제공되며, 기초 주식의 재판매를 위해 SEC 등록이 필요합니다.
Creative Medical Technology Holdings (NASDAQ: CELZ) a sécurisé des accords pour l'exercice immédiat de bons de souscription, générant environ 3,7 millions de dollars de produits bruts. L'accord implique des détenteurs de bons de souscription existants achetant 837 104 actions à 4,42 dollars par action, ces actions étant déjà enregistrées sous le formulaire S-1.
En échange de l'exercice immédiat en espèces, CELZ émettra de nouveaux bons de souscription non enregistrés pour un maximum de 1 674 208 actions à un prix d'exercice de 3,75 dollars par action, exerçables pendant cinq ans après l'approbation des actionnaires. La transaction, avec Roth Capital Partners en tant que conseiller financier, devrait se clôturer autour du 6 mars 2025.
L'entreprise prévoit d'utiliser les produits nets pour le fonds de roulement et des fins corporatives générales. Les nouveaux bons de souscription sont offerts par le biais d'un placement privé et nécessiteront une inscription auprès de la SEC pour la revente des actions sous-jacentes.
Creative Medical Technology Holdings (NASDAQ: CELZ) hat Vereinbarungen für die sofortige Ausübung von Warrants getroffen, die etwa 3,7 Millionen Dollar an Bruttoerlösen generieren. Die Vereinbarung umfasst bestehende Warrant-Inhaber, die 837.104 Aktien zu 4,42 Dollar pro Aktie kaufen, wobei diese Aktien bereits unter dem Formular S-1 registriert sind.
Im Austausch für die sofortige Barausübung wird CELZ neue nicht registrierte Warrants für bis zu 1.674.208 Aktien zu einem Ausübungspreis von 3,75 Dollar pro Aktie ausgeben, die fünf Jahre nach der Genehmigung durch die Aktionäre ausgeübt werden können. Die Transaktion, bei der Roth Capital Partners als Finanzberater fungiert, soll voraussichtlich um den 6. März 2025 abgeschlossen werden.
Das Unternehmen plant, die Nettoerlöse für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die neuen Warrants werden über eine Privatplatzierung angeboten und erfordern eine SEC-Registrierung für den Wiederverkauf der zugrunde liegenden Aktien.
- Secured $3.7M in immediate funding through warrant exercise
- Warrants exercised at premium price of $4.42 per share
- New warrants provide potential for additional future funding
- Potential dilution from 837,104 new shares being issued
- Additional dilution risk from 1,674,208 new warrant shares
- New warrants priced lower at $3.75 vs. original $4.42
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 837,104 shares of common stock of the Company originally issued in October 2024 at their current exercise price of
Roth Capital Partners is acting as the Company’s financial advisor for this transaction.
In consideration for the immediate exercise of the existing warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 1,674,208 shares of common stock, at an exercise price of
The transaction is expected to close on or about March 6, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology, and orthopedics and is traded on NASDAQ under the ticker symbol CELZ. For further information about the Company, please visit www.creativemedicaltechnology.com.
Forward-Looking Statements
This news release may contain forward-looking statements, including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions, which may involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Contact:
Creative Medical Technology Holdings, Inc.
IR@CreativeMedicalTechnology.com
Investor Relations:
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
FAQ
How much funding did Creative Medical Technology (CELZ) raise through warrant exercises in March 2025?
What are the terms of CELZ's new warrants issued in March 2025?
How many shares are being issued in CELZ's March 2025 warrant exercise?
What will CELZ use the $3.7 million warrant exercise proceeds for?
